Lebrikizumab Improves Hand and Face Dermatitis in Most Patients at 16 Weeks

Analysis of phase 3 trial data show about two-thirds of patients with atopic dermatitis who responded to the IL-13 inhibitor also saw benefit for difficult-to-treat hand and face eczema.

Related Keywords

Washington ,United States ,Jennye Murase , ,University Of California San Francisco ,Revolutionizing Atopic Dermatitis ,California San Francisco ,Eli Lilly Funded ,